デフォルト表紙
市場調査レポート
商品コード
1473724

せん妄市場の予測:~2030年

Delirium Market Research Report Forecast till 2030

出版日: | 発行: Market Research Future | ページ情報: 英文 132 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
せん妄市場の予測:~2030年
出版日: 2024年04月18日
発行: Market Research Future
ページ情報: 英文 132 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

せん妄の市場規模は、予測期間中に5.84%のCAGRで成長すると予測されています。

高齢化人口の増加、同定と診断の向上、技術の進歩が市場成長の原動力となっています。

高齢化はせん妄市場の重要な促進要因です。世界人口が高齢化する中で、せん妄の有病率は増加しています。高齢者は、基礎疾患、認知障害、多剤併用、入院などの要因により、せん妄に罹患しやすくなります。神経伝達物質の変化や認知予備能の低下など、加齢に伴う生理的変化もせん妄に対する脆弱性の一因です。

また、人口の高齢化は、せん妄の根本的なメカニズムを解明し、年齢に応じた介入の開発に焦点を当てた革新的な研究努力に影響を与えています。また、高齢者のせん妄管理を効果的に行うために必要な知識と技術を医療従事者に習得させるための、学際的な連携やトレーニングの重要性も強調されています。これらのことから、高齢者人口の増加がせん妄市場の拡大と発展の原動力となってます。

北米のせん妄市場は、高齢化と慢性疾患の増加により、2022年に最大の市場シェアを示しました。同地域の確立された医療インフラと先進的な医学研究が、せん妄管理における診断・治療イノベーションの成長に寄与しています。

欧州のせん妄市場は第2位の市場シェアを占めると予想されています。国別ではドイツが最大のシェアを占め、フランスが欧州地域で最も急成長すると予測されています。

当レポートでは、世界のせん妄の市場を調査し、市場の定義と概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブハンドブック

第2章 市場概要

第3章 調査手法

第4章 市場力学

  • 成長パラメーターマッピング: 促進要因
    • 高齢者人口の増加
    • 同定・診断の改善
    • 技術的に高度な治療に対する需要の増加
  • 課題
    • 治療費の高騰
    • データセキュリティへの脅威と厳格な規制遵守
  • 機会
    • 製薬企業や学術機関との連携

第5章 市場要因分析

  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析

第6章 世界のせん妄市場:タイプ別

  • 多動性
  • 低活動性
  • 混合

第7章 世界のせん妄市場:診断・治療別

  • 診断
    • 臨床検査
    • 理学的検査
    • 画像検査
  • 処理
    • 抗精神病薬
    • 支持療法

第8章 世界のせん妄市場:エンドユーザー別

  • 病院
  • 専門ケア
  • 研究センター

第9章 世界のせん妄市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 競合ダッシュボード
  • 企業市場シェア分析
  • 市場のディスラプターとイノベーター
  • 市場リーダーのよ採用戦略
  • 競合ベンチマーキング
  • 開発件数でトップの企業
  • 主要企業一覧:地域別
  • 企業株式
  • 主要企業の財務比較分析
  • 主な展開・成長戦略

第11章 企業プロファイル

  • OTSUKA PHARMACEUTICAL CO., LTD
  • MYLAN N.V
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • ZYDUS GROUP
  • GLENMARK PHARMACEUTICALS LTD
  • PFIZER
  • MYLAN N.V
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • GLENMARK PHARMACEUTICALS LTD
  • NOVARTIS AG

第12章 推奨事項・専門家の見解

第13章 MRFRの提供内容とチーム

図表

LIST OF TABLES

  • TABLE 1. LIST OF ASSUMPTIONS
  • TABLE 2. GLOBAL DELIRIUM MARKET ESTIMATES & FORECAST, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 3. GLOBAL DELIRIUM MARKET FOR HYPERACTIVE MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 4. GLOBAL DELIRIUM MARKET FOR HYPOACTIVE MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 5. GLOBAL DELIRIUM MARKET FOR MIXED MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 6. GLOBAL DELIRIUM MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 7. GLOBAL DELIRIUM MARKET FOR DIAGNOSIS MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 8. GLOBAL DELIRIUM MARKET FOR TREATMENT MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 9. GLOBAL DELIRIUM MARKET ESTIMATES & FORECAST, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 10. GLOBAL DELIRIUM MARKET FOR HOSPITALS MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 11. GLOBAL DELIRIUM MARKET FOR SPECIALITY CARE MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 12. GLOBAL DELIRIUM MARKET FOR RESEARCH CENTERS MARKET ESTIMATES & FORECAST, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 13. GLOBAL DELIRIUM MARKET MARKET, BY REGION, 2019-2030 (USD MILLION)
  • TABLE 14. NORTH AMERICA: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 15. NORTH AMERICA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 16. NORTH AMERICA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT 2019-2030 (USD MILLION)
  • TABLE 17. NORTH AMERICA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION
  • TABLE 18. U.S.: DELIRIUM MARKET, BY ACCESS, 2019-2030 (USD MILLION)
  • TABLE 19. U.S.: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 20. CANADA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 21. CANADA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 22. CANADA.: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 23. MEXICO: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 24. MEXICO: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 25. MEXICO.: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 26. EUROPE: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 27. EUROPE: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 28. EUROPE: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 29. EUROPE: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 30. GERMANY: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 31. GERMANY: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 32. GERMANY: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 33. FRANCE: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 34. FRANCE: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 35. FRANCE: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 36. UK: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 37. UK: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 38. UK: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 39. SPAIN: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 40. SPAIN: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 41. SPAIN: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 42. ITALY: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 43. ITALY: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 44. ITALY: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 45. REST OF EUROPE: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 46. REST OF EUROPE: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 47. REST OF EUROPE: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 48. ASIA PACIFIC: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 52. CHINA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 53. CHINA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 54. CHINA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 55. INDIA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 56. INDIA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 57. INDIA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 58. JAPAN: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 59. JAPAN: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 60. JAPAN: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 61. SOUTH KOREA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 62. SOUTH KOREA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 67. REST OF ASIA- PACIFIC: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 68. REST OF ASIA- PACIFIC: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 69. REST OF ASIA- PACIFIC: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 70. REST OF THE WORLD: DELIRIUM MARKET, BY COUNTRY, 2019-2030 (USD MILLION)
  • TABLE 71. REST OF THE WORLD: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 72. REST OF THE WORLD: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 73. REST OF THE WORLD: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 74. MIDDLE EAST AND AFRICA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 75. MIDDLE EAST AND AFRICA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 76. MIDDLE EAST AND AFRICA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION)
  • TABLE 77. LATIN AMERICA: DELIRIUM MARKET, BY TYPE, 2019-2030 (USD MILLION)
  • TABLE 78. LATIN AMERICA: DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT, 2019-2030 (USD MILLION)
  • TABLE 79. LATIN AMERICA: DELIRIUM MARKET, BY END USER, 2019-2030 (USD MILLION

LIST OF FIGURES

  • FIGURE 1. MARKET SYNOPSIS
  • FIGURE 2. RESEARCH PROCESS OF MRFR
  • TABLE 80. DROC ANALYSIS OF GLOBAL DELIRIUM MARKET, 2019-2030
  • FIGURE 3. DRIVERS IMPACT ANALYSIS: GLOBAL DELIRIUM MARKET MARKET
  • FIGURE 4. RESTRAINTS IMPACT ANALYSIS: GLOBAL DELIRIUM MARKET MARKET
  • FIGURE 5. SUPPLY /VALUE CHAIN: ANALYSIS: GLOBAL DELIRIUM MARKET
  • FIGURE 6. MARKET ATTRACTIVENESS ANALYSIS: GLOBAL DELIRIUM MARKET
  • FIGURE 7. GLOBAL DELIRIUM MARKET ANALYSIS BY TYPE
  • FIGURE 8. GLOBAL DELIRIUM MARKET ANALYSIS BY DIAGNOSIS AND TREATMENT
  • FIGURE 9. GLOBAL DELIRIUM MARKET ANALYSIS BY END USER
  • FIGURE 10. GLOBAL DELIRIUM MARKET ANALYSIS BY REGION
  • FIGURE 11. GLOBAL VASCULAR CLOSURE HYPERACTIVE MARKET: MARKET STRUCTURE
  • FIGURE 12. NORTH AMERICA DELIRIUM MARKET & MARKET SHARE BY COUNTRY (2019 VS 2030)
  • FIGURE 13. EUROPE MARKET SIZE & MARKET SHARE BY COUNTRY (2019 VS 2030)
  • FIGURE 14. ASIA-PACIFIC & MARKET SHARE BY COUNTRY (2019 VS 2030)
  • FIGURE 15. REST OF THE WORLD MARKET SIZE & MARKET SHARE BY COUNTRY (2019 VS 2030)
目次
Product Code: MRFR/Pharma/4394-CR

Market Overview

The Delirium Market is anticipated to register a CAGR of 5.84% during the review period. Developing maturing populace, further developed distinguishing proof and finding, and mechanical headways are driving the market development.

The maturing populace is a critical driver of the delirium market. As the worldwide populace encounters a segment shift towards more seasoned grown-ups, the pervasiveness of delirium increments. More seasoned people are more powerless to delirium because of variables, for example, hidden medical issue, mental debilitations, polypharmacy, and hospitalization. The physiological changes related with maturing, like modifications in synapses and diminished mental save, additionally add to the weakness to delirium. The maturing populace's effect on the delirium market is complex. Right off the bat, it prompts a more prominent number of delirium cases, provoking a higher interest for indicative instruments, mediations, and the executives' procedures.

Furthermore, the maturing populace impacts innovative work endeavors zeroed in on figuring out the fundamental systems of delirium and creating age-explicit mediations. It additionally highlights the significance of interdisciplinary joint effort and preparing to furnish medical care experts with the information and abilities fundamental for successful delirium the board in more seasoned grown-ups. In general, the developing maturing populace is a main thrust behind the extension and progression of the delirium market.

Market Segmentation

Based on kind, the Delirium Market is divided into three segments: Hyperactive, Hypoactive, and Mixed.

The segmentation of the delirium market is predicated on diagnosis and therapy, which comprises both diagnosis and treatment.

The market is divided into hospitals, specialty care, and research centers based on the end-user.

The North American Delirium market addressed the greatest market share in 2022 considering developing people and a rising in continuous disorders, there is an extended knowledge of delirium as a fundamental piece of patient thought. The region's well established clinical benefits establishment and high-level clinical assessment add to the improvement of expressive and medicinal progressions in delirium the board.

Europe Delirium market should address the second-greatest market share in light of the extraordinary prosperity courses of action and example towards organizing prosperity organizations, including directing.

The Asia-Pacific clinical consideration directing market should create at the speediest rate from 2023 to 2030. This is a direct result of the rising spending in clinical benefits, quickly creating clinical consideration establishment, creating care with respect to Delirium, and creating people in the region.

The Rest of the World integrates the Middle East, Africa, and Latin America. The chief variables affecting the advancement of Delirium are in the Middle East and Africa.

Key Market Players

The key market players are Mylan N.V (US), Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Zydus Group (India), Pfizer (India), Teva Pharmaceutical Industries Ltd (Israel), and Novartis AG (Switzerland).

TABLE OF CONTENTS

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS

1. EXECUTIVE'S HANDBOOK

  • 1.1. THE TOP PERFORMING SEGMENTS
  • 1.2. KEY TRENDS SUMMARIZED
  • 1.3. PRICING OUTLOOK
  • 1.4. STRATEGIC INSIGHTS
  • 1.5. WHO ARE THE KEY PLAYERS IN THE MARKET?

SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE

2. MARKET INTRODUCTION

  • 2.1. DEFINITION
  • 2.2. REPORT SEGMENTATION & SCOPE
  • 2.3. REGIONAL & COUNTRY LEVEL COVERAGE
  • 2.4. WHY YOU NEED THIS REPORT?

3. RESEARCH METHODOLOGY

  • 3.1. RESEARCH PROCESS
  • 3.2. SECONDARY RESEARCH
    • 3.2.1. DATA MINING & CONDENSATION
    • 3.2.2. SOURCES (ASSOCIATIONS, ORGANIZATIONS, MAGAZINES, PAID DATABASES)
  • 3.3. PRIMARY RESEARCH
    • 3.3.1. SAMPLE SIZE (DEMAND-SUPPLY, COMPANY TYPE, DESIGNATIONS, REGION)
    • 3.3.2. SOURCES
  • 3.4. FACTORIAL ANALYSIS & APPROACH SETTING
  • 3.5. ESTIMATION & FORECAST MODELS
  • 3.6. PRICING BASKETS
  • 3.7. ANALYST HOURS & TEAM

SECTION III: QUALITATIVE ANALYSIS

4. MARKET DYNAMICS

  • 4.1. INTRODUCTION
  • 4.2. GROWTH PARAMETERS MAPPED - DRIVERS
    • 4.2.1. GROWING AGING POPULATION
    • 4.2.2. IMPROVED IDENTIFICATION AND DIAGNOSIS
    • 4.2.3. INCREASING DEMAND FOR TECHNOLOGICALLY ADVANCED TREATMENT
  • 4.3. WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
    • 4.3.1. HIGH COST OF TREATMENT
    • 4.3.2. THREAT TO DATA SECURITY &STRICT REGULATORY COMPLIANCE
  • 4.4. OPPORTUNITIES
    • 4.4.1. COLLABORATION WITH PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS
    • 4.4.2. OPPORTUNITY
    • 4.4.3. OPPORTUNITY

5. MARKET FACTOR ANALYSIS

  • 5.1. VALUE CHAIN ANALYSIS
    • 5.1.1. R&D AND DESIGNING
    • 5.1.2. MANUFACTURING
    • 5.1.3. DISTRIBUTION & SALES
    • 5.1.4. POST SALES SERVICES
  • 5.2. PORTER'S FIVE FORCES MODEL
    • 5.2.1. BARGAINING POWER OF SUPPLIERS
    • 5.2.2. BARGAINING POWER OF BUYERS
    • 5.2.3. THREAT OF NEW ENTRANTS
    • 5.2.4. THREAT OF SUBSTITUTES
    • 5.2.5. INTENSITY OF RIVALRY
  • 5.3. COVID-19 IMPACT ANALYSIS
    • 5.3.1. IMPACT ON R&D
    • 5.3.2. IMPACT ON PRICING
    • 5.3.3. IMPACT ON REGIONS

SECTION IV: QUANTITATIVE ANALYSIS

6. GLOBAL DELIRIUM MARKET, BY TYPE (USD MILLION)

  • 6.1. INTRODUCTION
  • 6.2. HYPERACTIVE
    • 6.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPERACTIVE,-2030
  • 6.3. HYPOACTIVE
    • 6.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPOACTIVE,-2030
  • 6.4. MIXED
    • 6.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY MIXED,-2030

7. GLOBAL DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT (USD MILLION)

  • 7.1. INTRODUCTION
  • 7.2. DIAGNOSIS
    • 7.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS,-2030
    • 7.2.2. LABORATORY TESTS
    • 7.2.3. PHYSICAL EXAMINATION
    • 7.2.4. IMAGING TEST
  • 7.3. TREATMENT
    • 7.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TREATMENT,-2030
    • 7.3.2. ANTIPSYCHOTICS
    • 7.3.3. SUPPORTIVE CARE

8. GLOBAL DELIRIUM MARKET, BY END USER (USD MILLION)

  • 8.1. INTRODUCTION
  • 8.2. HOSPITALS
    • 8.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HOSPITALS,-2030
  • 8.3. SPECIALITY CARE
    • 8.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY SPECIALITY CARE,-2030
  • 8.4. RESEARCH CENTERS
    • 8.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY RESEARCH CENTERS,-2030

9. GLOBAL DELIRIUM MARKET, BY REGION (USD MILLION)

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
    • 9.2.2. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.2.3. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.2.4. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.2.5. US
    • 9.2.6. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.2.7. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.2.7.1. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.2.8. CANADA
      • 9.2.8.1. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.2.8.2. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.2.8.3. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.2.9. MEXICO
      • 9.2.9.1. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.2.9.2. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.2.9.3. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3. EUROPE
      • 9.3.1.1. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
      • 9.3.1.2. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.1.3. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.1.4. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.2. GERMANY
      • 9.3.2.1. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.2.2. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.2.3. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.3. FRANCE
      • 9.3.3.1. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.3.2. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.3.3. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.4. UK
      • 9.3.4.1. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.4.2. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.4.3. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.5. SPAIN
      • 9.3.5.1. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.5.2. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.5.3. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.6. ITALY
      • 9.3.6.1. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.6.2. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.6.3. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.3.7. REST OF EUROPE
      • 9.3.7.1. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.3.7.2. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.3.7.3. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4. ASIA-PACIFIC
    • 9.4.1. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
    • 9.4.2. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.3. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.4. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.5. CHINA
      • 9.4.5.1. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.5.2. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.5.3. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.6. INDIA
      • 9.4.6.1. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.6.2. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.6.3. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.7. JAPAN
      • 9.4.7.1. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.7.2. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.7.3. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.8. SOUTH KOREA
      • 9.4.8.1. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.8.2. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.8.3. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.9. AUSTRALIA
      • 9.4.9.1. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.9.2. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.9.3. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.4.10. REST OF ASIA-PACIFIC
      • 9.4.10.1. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.4.10.2. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.4.10.3. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.5. REST OF THE WORLD
    • 9.5.1. MIDDLE EAST & AFRICA
      • 9.5.1.1. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.5.1.2. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.5.1.3. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
    • 9.5.2. LATIN AMERICA
      • 9.5.2.1. LATIN AMERICA AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
      • 9.5.2.2. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
      • 9.5.2.3. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030

SECTION V: COMPETITIVE ANALYSIS

10. COMPETITIVE LANDSCAPE

  • 10.1. INTRODUCTION
  • 10.2. COMPETITION DASHBOARD
  • 10.3. COMPANY MARKET SHARE ANALYSIS,-23 (%)
  • 10.4. WHO ARE THE MARKET DISRUPTORS & INNOVATORS?
  • 10.5. WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS?
  • 10.6. COMPETITIVE BENCHMARKING
  • 10.7. THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DELIRIUM MARKET
  • 10.8. LIST OF KEY PLAYERS, BY REGION
  • 10.9. PUBLIC PLAYERS STOCK SUMMARY
  • 10.10. COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
  • 10.11. KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.11.1. NEW TYPE LAUNCH/SERVICE DEPLOYMENT
    • 10.11.2. MERGER & ACQUISITION
    • 10.11.3. JOINT VENTURES

11. COMPANY PROFILES

  • 11.1. OTSUKA PHARMACEUTICAL CO., LTD
    • 11.1.1. COMPANY OVERVIEW
    • 11.1.2. FINANCIAL OVERVIEW
    • 11.1.3. PRODUCT OFFERED
    • 11.1.4. KEY DEVELOPMENTS
    • 11.1.5. SWOT ANALYSIS
    • 11.1.6. KEY STRATEGIES
  • 11.2. MYLAN N.V
    • 11.2.1. COMPANY OVERVIEW
    • 11.2.2. FINANCIAL OVERVIEW
    • 11.2.3. PRODUCT OFFERED
    • 11.2.4. KEY DEVELOPMENTS
    • 11.2.5. SWOT ANALYSIS
    • 11.2.6. KEY STRATEGIES
  • 11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.3.1. COMPANY OVERVIEW
    • 11.3.2. FINANCIAL OVERVIEW
    • 11.3.3. PRODUCT OFFERED
    • 11.3.4. KEY DEVELOPMENTS
    • 11.3.5. SWOT ANALYSIS
    • 11.3.6. KEY STRATEGIES
  • 11.4. ZYDUS GROUP
    • 11.4.1. COMPANY OVERVIEW
    • 11.4.2. FINANCIAL OVERVIEW
    • 11.4.3. PRODUCT OFFERED
    • 11.4.4. KEY DEVELOPMENTS
    • 11.4.5. SWOT ANALYSIS
    • 11.4.6. KEY STRATEGIES
  • 11.5. GLENMARK PHARMACEUTICALS LTD
    • 11.5.1. COMPANY OVERVIEW
    • 11.5.2. FINANCIAL OVERVIEW
    • 11.5.3. PRODUCT OFFERED
    • 11.5.4. KEY DEVELOPMENTS
    • 11.5.5. SWOT ANALYSIS
    • 11.5.6. KEY STRATEGIES
  • 11.6. PFIZER
    • 11.6.1. COMPANY OVERVIEW
    • 11.6.2. FINANCIAL OVERVIEW
    • 11.6.3. PRODUCT OFFERED
    • 11.6.4. KEY DEVELOPMENTS
    • 11.6.5. SWOT ANALYSIS
    • 11.6.6. KEY STRATEGIES
  • 11.7. MYLAN N.V
    • 11.7.1. COMPANY OVERVIEW
    • 11.7.2. FINANCIAL OVERVIEW
    • 11.7.3. PRODUCT OFFERED
    • 11.7.4. KEY DEVELOPMENTS
    • 11.7.5. SWOT ANALYSIS
    • 11.7.6. KEY STRATEGIES
  • 11.8. TEVA PHARMACEUTICAL INDUSTRIES LTD
    • 11.8.1. COMPANY OVERVIEW
    • 11.8.2. FINANCIAL OVERVIEW
    • 11.8.3. PRODUCT OFFERED
    • 11.8.4. KEY DEVELOPMENTS
    • 11.8.5. SWOT ANALYSIS
    • 11.8.6. KEY STRATEGIES
  • 11.9. GLENMARK PHARMACEUTICALS LTD
    • 11.9.1. COMPANY OVERVIEW
    • 11.9.2. FINANCIAL OVERVIEW
    • 11.9.3. PRODUCT OFFERED
    • 11.9.4. KEY DEVELOPMENTS
    • 11.9.5. SWOT ANALYSIS
    • 11.9.6. KEY STRATEGIES
  • 11.10. NOVARTIS AG
    • 11.10.1. COMPANY OVERVIEW
    • 11.10.2. FINANCIAL OVERVIEW
    • 11.10.3. PRODUCT OFFERED
    • 11.10.4. KEY DEVELOPMENTS
    • 11.10.5. SWOT ANALYSIS
    • 11.10.6. KEY STRATEGIES

12. RECOMMENDATIONS & EXPERT INSIGHTS

  • 12.1. WHAT IS THE SHORT-TERM VS LONG-TERM OUTLOOK FOR DELIRIUM MARKET?
  • 12.2. WHO ARE THE PLAYERS TO LOOK OUT FOR?
  • 12.3. WHAT WILL THE PRODUCT MIX LOOK IN COMING YEARS?

13. MRFR OFFERINGS & TEAM

  • 13.1. CITATIONS & MEDIA
  • 13.2. OUR REGIONAL REPRESENTATIVES
  • 13.3. RELATED REPORTS
  • 13.4. OUR DOMAIN COVERAGE